EDITORIAL SECTION

Articles

Antibody-Drug Conjugates (ADCs): Driving the Next Generation of Precision Oncology

An antibodydrug conjugate is a targeted cancer therapy that links a potent cytotoxic drug to a monoclonal antibody through a chemical linker so the antibody delivers the payload directly to tumour cells expressing a chosen antigen The design widens the therapeutic window it concentrates cytotoxic activity where the target is expressed and limits the systemic exposure that constrains conventional c...

How EU Pharmaceutical Reforms Could Change Drug Development and Market Access

For more than two decades the rules governing how medicines are developed authorised and protected in the European Union have rested on a directive from and a regulation from That foundation is about to be replaced The European Commission tabled its proposal for a new directive and regulation in April the European Parliament set its position in April

The Growing Role of Real-World Evidence in European Drug Development

For decades the randomised controlled trial has been the gold standard of pharmaceutical evidence in Europe and it still is Yet the evidence that shapes a medicines journey from laboratory to patient is no longer confined to the controlled world of the trial protocol Electronic health records disease registries insurance claims biobanks and patientreported data are now being mobilised at continent...

Unlocking Value: Data Science Applications in Pharmacoeconomics

In the realm of healthcare where every decision has significant financial implications pharmacoeconomics plays a pivotal role It involves the evaluation of the economic impact of pharmaceutical products and services

Using Mass Spectrometry as Quality Control in Medicinal Cannabis

Cannabis plants contain a wide variety of complex compounds including phytocannabinoids terpenoids and flavonoids found mainly in the inflorescences Major phytocannabinoids like CBD and THC have beneficial effects on human health

Pharmaceutical Market Access and Reimbursement Strategies in Europe

Getting EMA approval is a milestone but it isnt a launch In Europe a medicine can be authorized in every member state and still not reach a single patient until each country agrees on its price and who pays for it That gap between approval and access is where pharmaceutical market access is won or lost

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG

PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys